Investigation Report on China's Atorvastatin Market 2021-2025
No. of Pages: 50
Atorvastatin is a statin drug, which is used to lower blood cholesterol levels. This common drug is mainly used to treat high cholesterol, hyperlipidemia, and
|
19-Jul-2021
|
2600
|
Investigation Report on China's Leuprorelin Market 2021-2025
No. of Pages: 50
Leuprolide is a synthetic gonadotropin drug used to treat hormone-responsive cancers such as prostate cancer and breast cancer. It can also be used to treat
|
08-Jun-2021
|
2600
|
Investigation Report on China's Moxifloxacin Market 2021-2025
No. of Pages: 50
Moxifloxacin is a fourth-generation synthetic quinolone antibacterial drug (8-methoxy-fluoroquinolone antibiotic) developed by Bayer Vital GmbH. It was approved for marketing by the FDA in December
|
08-Jun-2021
|
2600
|
Investigation Report on China's Acetylcysteine Market 2021-2025
No. of Pages: 50
Acetylcysteine, also known as N-acetylcysteine (NAC), is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with
|
08-Jun-2021
|
2600
|
Investigation Report on Global and China's MOSFET Market 2021-2025
No. of Pages: 50
MOSFET is an acronym for Metal Oxide Semiconductor Field Effect Transistor, also known as MOS, MOS transistor. The name "metal–oxide–semiconductor" (MOS) typically refers to a
|
08-Jun-2021
|
2600
|
Investigation Report on China's Enteral Nutrition Market 2021-2025
No. of Pages: 50
Enteral nutrition is mainly used for preoperative feeding of patients with anorexia and related diseases, including mechanical gastrointestinal dysfunction, critical illness and malnutrition. It was
|
08-Jun-2021
|
2600
|
Investigation Report on China's Insulin Glargine Market 2021-2025
No. of Pages: 50
Insulin Glargine is a long-acting human insulin analog that can control the patient's blood sugar more effectively and steadily. It is often used to treat
|
08-Jun-2021
|
2600
|
Investigation Report on China's Emtricitabine/Tenofovir Market 2021-2025
No. of Pages: 50
Emtricitabine/Tenofovir is the first HIV drug approved for prophylaxis. It was developed by Gilead Sciences Inc (the original drug is called TRUVADA). Its product was
|
08-Jun-2021
|
2600
|
Investigation Report on China's Recombinant human thrombopoietin (rhTPO) Market 2021-2025
No. of Pages: 50
Recombinant Human Thrombopoietin(rhTPO), developed by Shenyang Sansheng Pharmaceutical Co., Ltd., was approved for marketing in China in 2005 and used to treat thrombocytopenia caused by
|
08-Jun-2021
|
2600
|
Investigation Report on China's Express Delivery Industry 2021-2025
No. of Pages: 50
Express delivery is a door-to-door logistics activity with postal functions, which means express companies use rail, road, and air transportation to quickly deliver customers' goods.
According
|
08-Jun-2021
|
2600
|
Investigation Report on China's Hydrotalcite Market, 2021-2025
No. of Pages: 50
Hydrotalcite is suitable for acute and chronic gastritis, reflux esophagitis, gastric and duodenal ulcers, stomach pain, heartburn, acid belching, fullness and other uncomfortable symptoms related
|
08-Jun-2021
|
2600
|
Investigation Report on China's Goserelin Market 2021-2025
No. of Pages: 50
Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Goserelin is developed by AstraZeneca, is mainly used to treat advanced breast and
|
08-Jun-2021
|
2600
|
Investigation Report on China's Levofloxacin Market 2021-2025
No. of Pages: 50
Levofloxacin, developed by Daiichi Sankyo, is used to treat bacterial infectious diseases such as community pneumonia, sinusitis, urinary tract infections. Levofloxacin tablets were approved in
|
08-Jun-2021
|
2600
|
Investigation Report on China's Doxorubicin Market 2021-2025
No. of Pages: 50
Doxorubicin belongs to the anthracycline class (Anthracycline) antibiotics, which can inhibit the synthesis of RNA and DNA. It has a strong inhibitory effect on RNA
|
08-Jun-2021
|
2600
|
Investigation Report on China's Dexmedetomidine Market 2021-2025
No. of Pages: 50
Dexmedetomidine is a highly selective α2-adrenergic receptor agonist. It is mainly used clinically for the sedation of tracheal intubation and mechanical ventilation in surgical patients
|
08-Jun-2021
|
2600
|
Investigation Report on China's Anlotinib Market 2021-2025
No. of Pages: 50
Anlotinib is an oral multi-targeting small-molecule tyrosine kinase inhibitor that can target multiple angiogenic factor receptors to inhibit tumor angiogenesis. It can be used for
|
08-Jun-2021
|
2600
|
Investigation Report on China's Rabeprazole Market 2021-2025
No. of Pages: 50
Rabeprazole is a kind of proton pump inhibitor (PPI) gastric acid inhibitor. It is used for the treatment of gastroesophageal reflux disease and maintenance treatment
|
04-Jun-2021
|
2600
|
Investigation Report on China's Ruxolitinib Market 2021-2025
No. of Pages: 50
Ruxolitinib was developed by Novartis Pharma Schweiz AG. It is an orally bioavailable Janus-associated kinase (JAK) inhibitor with selectivity for subtypes JAK1 and JAK2. Its
|
04-Jun-2021
|
2600
|
Investigation Report on China's Omalizumab Market 2021-2025
No. of Pages: 50
Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA
|
04-Jun-2021
|
2600
|
Investigation Report on China's Daratumumab Market 2021-2025
No. of Pages: 50
Daratumumab, developed by Johnson & Johnson, is a monoclonal antibody available for the treatment of myeloma. Its product DARZALEX was approved for the treatment of
|
04-Jun-2021
|
2600
|
